Explore HIV Drug Resistance and Molecular Research Advances

Understanding HIV Drug Resistance and Its Molecular Basis

HIV drug resistance occurs when genetic changes in the virus affect the ability of antiretroviral medicines to prevent viral replication. HIV reproduces rapidly, and genetic mutations can emerge during this process. Some mutations reduce the effectiveness of specific drugs or drug classes. Resistance may develop during treatment or be transmitted when a person acquires HIV that already contains resistance-associated mutations.

Molecular research examines how these genetic changes influence the interaction between HIV and antiretroviral medicines.

Important concepts include:

• Genetic mutations: Changes in viral genetic material that may reduce drug susceptibility.
• Transmitted resistance: Drug-resistant HIV acquired during infection.
• Acquired resistance: Resistance that develops during exposure to antiretroviral medicines.
• Viral replication: The process through which HIV produces new copies of itself.

Understanding these mechanisms helps researchers and healthcare professionals evaluate treatment effectiveness and resistance patterns.

Molecular Research Advances in HIV Resistance Testing

HIV drug resistance testing identifies genetic mutations associated with reduced susceptibility to antiretroviral medicines. Genotypic testing examines the virus's genetic material to identify resistance-associated changes. Healthcare professionals can use test results, alongside treatment history and other clinical information, to support decisions about antiretroviral regimens.

Recent research has focused on improving access to testing, monitoring resistance to integrase strand transfer inhibitors, and strengthening laboratory surveillance.

Key areas of research include:

• Genetic sequencing: Examining viral genetic material to identify mutations.
• Resistance surveillance: Tracking resistance patterns across populations and treatment settings.
• Laboratory accessibility: Developing affordable testing approaches for low and middle income countries.
• Integrase inhibitor research: Studying resistance associated with medicines targeting HIV integrase.

In January 2025, WHO reported on efforts to accelerate affordable HIV drug resistance testing, including improving testing feasibility and supporting treatment decisions for people experiencing treatment failure.

Current Scientific Developments and Treatment Research

Molecular research continues to examine resistance associated with different antiretroviral drug classes. The 2025 International Antiviral Society USA update on HIV 1 drug resistance mutations incorporates research findings relevant to the effects of mutations on currently available medicines. These resources help inform scientific understanding and clinical treatment considerations.

The World Health Organization's 2026 HIV drug resistance fact sheet also highlights ongoing surveillance of dolutegravir resistance and the importance of viral load monitoring. Although dolutegravir remains an effective HIV treatment, resistance can emerge in some treatment settings.

Research priorities include:

• Improving resistance detection methods.
• Studying genetic mutations associated with treatment failure.
• Expanding resistance surveillance in different populations.
• Investigating resistance linked to HIV prevention medicines.

These developments support continuing research into effective treatment strategies and public health monitoring.

HIV drug resistance and molecular research provide important scientific knowledge about how genetic changes influence antiretroviral treatment. Genetic testing, resistance surveillance, and laboratory innovation contribute to understanding resistance patterns and supporting evidence-based HIV care. Ongoing research remains important for protecting the effectiveness of available medicines and improving access to appropriate testing and treatment.